News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Important Ordering Details

Custom Ordering Details: Sections are cut freshly upon ordering. Please allow up to three business days for your product to be processed.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Description

Each control slide contains formalin fixed, paraffin-embedded HeLa cells, untreated, treated with Human Interferon-α1 (hIFN-α1) #8927 or treated with Human Epidermal Growth Factor (hEGF) #8916 that serve as a control for Phospho-Stat1 (Tyr701), Phospho-Stat3 (Tyr705) and Phospho-Stat5 (Tyr694) immunostaining. Western blot analysis was performed on extracts derived from the same cells to verify the efficacy of the hIFN-α1 and hEGF treatments. SignalSlide® Phospho-Stat1/3/5 IHC Control slides have not been tested as controls for Phospho-Stat1 (Ser727) or Phospho-Stat3 (Ser727) immunostaining.

To be used with antibodies: 9167, 9175, 9145, 4113, 4904, 9139, 9314, 9359.


Stat proteins serve as transcription factors in growth and survival pathways stimulated by growth factor and cytokine activation of receptor proteins. Receptor activation promotes tyrosine phosphorylation of Stat proteins, resulting in Stat dimerization and translocation to the nucleus where they regulate expression of numerous proteins that control cell growth, survival, differentiation and pathogen resistance (1). Stat1 is essential in IFN-α and IFN-γ stimulated pathways and is abnormally activated in many tumors (2,3). Both Stat1α (91 kDa) and Stat1β (84 kDa) isoforms are activated by IFN-α but only Stat1α responds to IFN-γ. Phosphorylation of Stat1 at Tyr701 induces Stat1 dimerization, nuclear translocation and DNA binding (4). Transcription factor Stat3 possesses oncogenic potential and anti-apoptotic activities; a number of human tumors display constitutively activated Stat3 (5,6). Activation of Stat3 follows phosphorylation at Tyr705, resulting in dimerization, nuclear translocation and DNA binding (7). Expression of Stat3α (86 kDa) and Stat3β (79 kDa) isoforms correlates with cell type, ligand and cell maturation stage (8). Phosphorylation of Stat5a at Tyr694 is essential for transcription factor activation (9). Stat5 is activated by interleukins and other cytokines (i.e. CSF1); presence of phosphorylated Stat5 is in some IL-3-treated cells suggests a role in angiogenesis and cell motility (10). Altered Stat5 expression and activity is associated with abnormal cell proliferation and apoptosis in some forms of leukemia (11).


1.  Ihle, J.N. (2001) Curr Opin Cell Biol 13, 211-7.

2.  Bromberg, J. (2002) J Clin Invest 109, 1139-42.

3.  Darnell, J.E. (1997) Science 277, 1630-5.

4.  Catlett-Falcone, R. et al. (1999) Immunity 10, 105-15.

5.  Ihle, J.N. et al. (1994) Trends Biochem. Sci. 19, 222-227.

6.  Garcia, R. and Jove, R. (1998) J Biomed Sci 5, 79-85.

7.  Gouilleux, F. et al. (1994) EMBO J 13, 4361-9.

8.  Biethahn, S. et al. (1999) Exp Hematol 27, 885-94.

9.  Buitenhuis, M. et al. (2004) Int J Biochem Cell Biol 36, 2120-4.

10.  Frank, D.A. (1999) Mol. Med. 5, 432-456.

11.  Baśkiewicz-Masiuk, M. et al. (2003) Cell Prolif 36, 265-78.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
SignalSlide® is a trademark of Cell Signaling Technology, Inc.